Corticosteroid Risk Function of Severe Infection in Primary XXXX Adults. A Nationwide Nested Case-Control Study.

@entity1 @entity281 @entity229 @entity3039
Corticosteroid (CS)-related @entity281 risk in @entity3039 ( @entity3039 ) is unknown. The aim of this study was to assess the adjusted CS risk function of severe @entity281 in persistent or chronic primary @entity3039 adults. We designed a nested case-control study in the FAITH cohort. This cohort is built through the French national health insurance database named SNIIRAM and includes all treated incident persistent or chronic primary @entity3039 adults in France (ENCePP n  4574). @entity1 who entered the FAITH cohort between 2009 and 2012 were eligible (n = 1805). Cases were @entity1 with @entity281 as primary diagnosis code during hospitalization. Index date was the date of first hospitalization for @entity281 . A 2:1 matching was performed on age and entry date in the cohort. Various CS exposure time-windows were defined: current user, exposure during the 1/3/6 months preceding index date and from the entry date. CS doses were converted in @entity229 equivalent (PEQ). The cumulative CS doses were averaged in each time-window to obtain daily PEQ dosages. Each CS exposure definition was assessed using multivariate conditional regression models. During the study period, 161 cases (9 opportunistic) occurred. The model with the best goodness of fit was CS exposure during the month before the index date (OR: 2.48, 95% CI: 1.61-3.83). The dose-effect relation showed that the risk existed from averaged daily doses >= 5 mg PEQ (vs. <5 mg: 2.09, 95% CI: 1.17-3.71). The risk of @entity281 was mainly supported by current or recent exposure to CS, even with low doses.
